Understanding Obesity as a Medical Condition
Obesity is a chronic, progressive metabolic disease - not a failure of willpower. This is one of the most important shifts in medical understanding over the past two decades. Research has conclusively demonstrated that obesity involves complex interactions between genetics, hormonal signaling, brain chemistry, gut microbiome composition, environmental factors, and metabolic adaptation. When a person gains weight and then attempts to lose it, the body actively fights to return to its higher weight through hormonal changes that increase hunger and reduce metabolic rate.
The statistics underscore the scope of the problem. Over 40% of American adults have obesity, and nearly 10% have severe obesity. Obesity significantly increases the risk of type 2 diabetes, cardiovascular disease, certain cancers, sleep apnea, joint disorders, and premature death. Traditional approaches - diet and exercise alone - produce meaningful long-term weight loss in fewer than 5% of patients, not because people lack discipline, but because the biological mechanisms working against weight loss are powerful.
This understanding has driven a fundamental rethinking of treatment approaches. Just as hypertension and diabetes are treated with medications that address their underlying biological mechanisms, obesity can now be treated with pharmacotherapy that targets the hormonal and neurological pathways driving excessive weight gain. Peptide therapy represents the most significant advancement in this area.
How Peptides Support Weight Loss
GLP-1 receptor agonists are a drug class studied for weight management. Incretins are gut hormones released after eating that regulate blood sugar, appetite, and metabolism; the two key incretins are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
In published clinical trials, GLP-1 receptor agonists such as semaglutide were studied for their action on satiety centers in the brain, on gastric emptying, and on insulin sensitivity, and tirzepatide was studied as a dual agonist that adds GIP receptor activity. Those trials studied the manufacturers' products, which are FDA-approved. The compounded preparations were not studied in these trials, and results are not guaranteed.
A clinician may also discuss compounded glutathione or NAD+ with some patients. Your physician decides whether any adjunct is appropriate after reviewing your intake and labs.
Which Peptides Are Used for Weight Loss?
The Pep Club catalog includes compounded GLP-1 therapy alongside other weight and metabolic options a clinician may consider. Through The Pep Club, compounded semaglutide and compounded tirzepatide are prescribed by U.S.-licensed physicians and dispensed by state-licensed pharmacies, including 503A compounding pharmacies. Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients. A compounded preparation is not a generic version of, and is not the same as, any FDA-approved medication. It is prescribed only when a licensed provider decides it is appropriate for you.
Compounded semaglutide is administered as a once-weekly subcutaneous injection with gradual dose escalation to the maintenance dose. Compounded tirzepatide is dosed similarly but with its own titration schedule.
For adjunct support during weight loss, compounded glutathione (antioxidant) or compounded NAD+ (cellular coenzyme) may be considered by your physician. The full catalog is decided patient-by-patient at consultation based on medical history, BMI, metabolic markers, and weight loss goals.
What the Published Research Studied
Research note
The STEP trials for semaglutide and the SURMOUNT trials for tirzepatide are large randomized, placebo-controlled trials published in the New England Journal of Medicine and other peer-reviewed journals. They looked at body weight and at related markers such as blood pressure, cholesterol, triglycerides and blood-sugar control, and the SELECT trial looked at cardiovascular events. Those trials studied the manufacturers' products, which are FDA-approved. The compounded preparations were not studied in these trials, and results are not guaranteed.
Long-term data is encouraging but also highlights the chronic nature of obesity treatment. Studies that followed patients after discontinuation of GLP-1 therapy showed significant weight regain, reinforcing that obesity is a chronic condition requiring ongoing management - similar to how blood pressure medication must be continued to maintain its effects. This is not a limitation of the therapy but rather a reflection of the underlying disease biology.
The Pep Club Weight Management Approach
At The Pep Club, weight management is treated as a comprehensive medical program, not a simple prescription. The process begins with a detailed medical intake that assesses your weight history, previous weight loss attempts, eating patterns, activity level, sleep quality, stress factors, current medications, and any relevant medical conditions. This information helps your physician understand the full picture of your metabolic health.
Your physician consultation includes a review of lab work - typically including metabolic panel, lipid panel, thyroid function, HbA1c, and other relevant markers - to identify any underlying conditions contributing to weight gain or that may affect treatment selection. Based on this comprehensive evaluation, your physician recommends a personalized treatment plan that may include one or more peptide therapies along with guidance on nutrition, physical activity, and behavioral strategies.
Weight management is a marathon, not a sprint. You can report a side effect from your portal at any time, and any change to your dose is a clinician's decision.
Frequently asked
How much weight can I expect to lose with peptide therapy?
Results vary from person to person, and results are not guaranteed. Your clinician discusses realistic expectations with you at consultation, based on your starting point, medical history and treatment plan. Published clinical trials were conducted on FDA-approved products, not on compounded preparations.
Will I regain weight if I stop the medication?
Research shows that weight regain is common after discontinuing GLP-1 therapy, because obesity is a chronic metabolic condition. This is similar to how blood pressure rises again when medication is stopped. Continued therapy, dose adjustment and transition planning are options a clinician may consider.
Are weight loss peptides safe?
Semaglutide and tirzepatide have been studied in large clinical trials. Those trials studied the manufacturers' products, which are FDA-approved. The compounded preparations were not studied in these trials, and results are not guaranteed. Like all medications, they have potential side effects - most commonly nausea and other GI symptoms. The compounded preparations available through The Pep Club are prepared and dispensed by state-licensed pharmacies, including 503A compounding pharmacies, under U.S.-licensed physician supervision. Your physician will evaluate your medical history to decide whether a therapy is appropriate for you.
Do I need to diet and exercise while taking weight loss peptides?
Yes. Peptide therapy for weight loss is intended to be used alongside lifestyle modifications - reduced caloric intake and increased physical activity. Medication is not a substitute for a healthy diet and regular exercise, which matter for your overall health whatever your treatment plan.